Basic Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Nov 21, 2020; 26(43): 6822-6836
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6822
Table 1 Categories used to classify ampullary adenocarcinomas

Pure histological classification
Basal histological classification
Molecular and histological classification
AACs5 Categories4 Categories3 Categories
TubularPure INTPure INTINT
Mixed INT-predominantMixed
Mixed PB-predominantPB
Pure PBPure PB
Non-tubularOtherOtherOther
Table 2 Immunophenotypical characterization of ampullary adenocarcinomas
Ref.Markers
Number
CK7
CK17
CK20
CDX2
MUC1
MUC2
Chang et al[11], 2013XX2
Kumari et al[22], 2013XXXXXX6
Ang et al[18], 2014XXXX4
Fernández Moro et al[16], 2016XX2
Reid et al[15], 20160
Liu et al[24], 2019XXXXXX6
Moekotte et al[31], 2018XXXX4
Al Abbas et al[30], 2019XXXX4
Abraham et al[17], 2020XX2
Total33%22%67%78%78%56%Mean3.33
Table 3 Patient characteristics
Patient characteristics
n
Age, mean ± SD (yr)72.9 ± 8.1
M/F11/10
BMI, mean ± SD (kg/m2)22.9 ± 3.9
ASA I, n (%)3 (14.2)
ASA II, n (%)6 (28.6)
ASA III, n (%)11 (52.4)
ASA IV, n (%)1 (4.8)
Comorbidity, n (%)16 (76.1)
Cardiovascular disease, n (%)6 (28.6)
COPD, n (%)6 (28.6)
Hypertension, n (%)10 (47.6)
Diabetes mellitus, n (%)3 (14.2)
Symptomatic, n (%)12 (57.1)
Jaundice, n (%)7 (58.3)
Pain, n (%)3 (25.1)
Nausea or Vomiting, n (%)1 (8.3)
Loss of weight, n (%)1 (8.3)
Placement of PTBD or biliary endoprothesis, n (%)4 (33.3)
CA 19.9, mean ± SD (U/mL)37.1 ± 53.2
Neoadjuvant therapy, n (%)0 (0)
Table 4 Post-operative data
LOS, mean ± SD (d)
15.4 ± 6.2
Overall complications, n (%)7 (33.3)
Clavien-Dindo > III, n (%)3 (14.2)
Reoperation, n (%)2 (9.5)
30-d mortality, n (%)0 (0)